Vela Technologies PLC - Bradford, England-based investment firm focused on early-stage and pre-IPO disruptive technology investments - Notes announcement by Conduit Pharmaceuticals Ltd that it intends to become a publicly traded company on the Nasdaq in the US through a merger with special purpose acquisition firm Murphy Cannon Acquisition Corp. The deal is expected to generate $149.7 million worth of proceeds for Conduit. Vela holds an interest in the commercialisation of AZD1656, a possible Covid-19 treatment, and one of Conduit’s assets.

Current stock price: 0.028 pence, closing 50% higher in London on Wednesday

12-month change: down 54%

Copyright 2022 Alliance News Limited. All Rights Reserved.